Optimize Patient Management

Health Care Providers

The DiviTum® TKa test can help oncologists make confident treatment decisions

  • Allows health care providers to track a patient’s response early on—and at any time
    point as clinically indicated throughout treatment.
  • Complements traditional imaging—particularly if CT scans are difficult
    to interpret; assesses non-measurable disease that may not be
    detected with conventional imaging

DiviTum TKa is a tool that can help guide more personalized treatment strategies for post-menopausal women diagnosed with HR+ metastatic breast cancer.

Thymidine kinase (TK) plays a key role in DNA synthesis and cell proliferation. Studies have shown that TK activity (TKa) is elevated in actively proliferating cancer.1,2

The DiviTum® TKa test helps you determine which patients are—or are not—responding optimally to CDK4/6 inhibitor therapy and may benefit from continuing therapy.3,4


1. Bitter EE, et al. Thymidine kinase 1 through the ages: a comprehensive review. Cell Biosci. 2020;10(1):138.

2. Larsson AM, et al. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer. Sci Rep. 2020;10(1):4484.

3. Malorni L, et al; International Breast Cancer Study Group; Breast International Group and PYTHIA Collaborators. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. Eur J Cancer. 2022;164:39-51.

4. Malorni L, et al. Serum thymidine kinase activity in patients with HRpositive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. Eur J Cancer. 2023; 186: 1–11. Eur J Cancer 2023; 186: 1–11.


Please specify your home location